TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant 4 Progression 5

Archive ouverte

Baylot, Virginie | Karaki, Sara | Rocchi, Palma

Edité par CCSD -

International audience. Prostate cancer (PC) is the second most common cause of cancer-related 7 mortality in men in the western world after lung cancer. Many patients are not 8 candidates for resection given the advanced stage of their cancer. The primary 9 treatment for advanced PC is the castration therapy which supresses the production 10 of androgens, hormone that promotes PC growth. Despite the efficiency of the 11 castration therapy, most patients develop castration resistant disease which remains 12 uncurable. Clearly, novel approaches are required to effectively treat castration 13 resistant PC (CRPC). New strategies that identify the molecular mechanisms by 14 which PC becomes resistant to conventional therapies may enable the identification 15 of novel therapeutic targets that could improve clinical outcome. Recent studies 16 have demonstrated the implication of TCTP's over-expression in PC and CRPC, 17 and its role in resistance to treatment. TCTP's interaction with p53 and their 18 negative feedback loop regulation have also been described to be causal for PC 19 progression and invasion. A novel nanotherapy that inhibits TCTP has been devel-20 oped as a new therapeutical strategy in CRPC. This chapter will highlight the role of 21 TCTP as new therapeutic target in PC, in particular, therapy-resistant advanced PC 22 and report the development of novel nanotherapy against TCTP that restore treat-23 ment-sensitivity in CRPC that deserve to be tested in clinical trial.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion